Photo taken from Vivek Subbiah/X
Jan 21, 2024, 16:25
Vivek Subbiah: Catching up about simple/pragmatic trial designs in oncology at ASCO GI24 meeting
Vivek Subbiah shared on X:
“So nice catching up with the amazing Timil Patel from the US FDA about simple/pragmatic trial designs in oncology at ASCO GI24 meeting.
Since clinical trials in oncology that are submitted for regulatory review are becoming more and more complex – Dr. Patel and colleagues from the FDA Oncology, US FDA recently in a commentary called upon the drug development community to find ways to make clinical trials simpler.
When less is more – reducing complexity in cancer trials.”
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33